Theriva Biologics, Inc. (TOVX)
USD 1.17
(-1.68%)
USD 1.17
(-1.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -19.85 Million USD | -2.34% |
| 2022 | -21.58 Million USD | -50.31% |
| 2021 | -14.18 Million USD | -43.33% |
| 2020 | -9.95 Million USD | 35.43% |
| 2019 | -15.42 Million USD | 27.87% |
| 2018 | -17.29 Million USD | 41.81% |
| 2017 | -26 Million USD | 27.25% |
| 2016 | -39.09 Million USD | -36.15% |
| 2015 | -40.9 Million USD | -75.01% |
| 2014 | -20.48 Million USD | -72.56% |
| 2013 | -11.53 Million USD | 28.66% |
| 2012 | -17.22 Million USD | -328.84% |
| 2011 | -7.48 Million USD | -227.8% |
| 2010 | -1.22 Million USD | 62.39% |
| 2009 | -3.33 Million USD | 52.9% |
| 2008 | -6.91 Million USD | 30.43% |
| 2007 | -9.93 Million USD | -144.71% |
| 2006 | -4.06 Million USD | -217.43% |
| 2005 | -1.27 Million USD | 0.0% |
| 2002 | -8.09 Million USD | 17.04% |
| 2001 | -9.75 Million USD | -52.05% |
| 2000 | -6.41 Million USD | -166.74% |
| 1999 | -5.38 Million USD | 18.69% |
| 1998 | -5.15 Million USD | 183.51% |
| 1997 | -7.9 Million USD | -31.08% |
| 1996 | -7.4 Million USD | -1.37% |
| 1995 | -7.3 Million USD | -14.06% |
| 1994 | -6.3 Million USD | -82.86% |
| 1993 | -3.6 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.38 Million USD | 13.0% |
| 2024 Q1 | -5.35 Million USD | 8.81% |
| 2023 Q4 | -5.83 Million USD | -38.43% |
| 2023 Q3 | -4.21 Million USD | 27.07% |
| 2023 Q1 | -5.18 Million USD | 29.03% |
| 2023 Q2 | -5.78 Million USD | -11.57% |
| 2023 FY | - USD | -2.34% |
| 2022 Q4 | -7.3 Million USD | -46.64% |
| 2022 Q3 | -4.98 Million USD | -0.46% |
| 2022 Q2 | -4.95 Million USD | -17.74% |
| 2022 Q1 | -4.21 Million USD | 20.02% |
| 2022 FY | - USD | -50.31% |
| 2021 Q4 | -5.26 Million USD | -61.65% |
| 2021 FY | - USD | -43.33% |
| 2021 Q1 | -2.5 Million USD | -19.24% |
| 2021 Q2 | -3.17 Million USD | -26.76% |
| 2021 Q3 | -3.25 Million USD | -2.61% |
| 2020 FY | - USD | 35.43% |
| 2020 Q1 | -2.97 Million USD | 5.77% |
| 2020 Q2 | -2.83 Million USD | 4.68% |
| 2020 Q3 | -2.05 Million USD | 27.3% |
| 2020 Q4 | -2.1 Million USD | -2.04% |
| 2019 Q2 | -3.57 Million USD | -1.94% |
| 2019 Q4 | -3.15 Million USD | 39.17% |
| 2019 Q3 | -5.18 Million USD | -44.83% |
| 2019 FY | - USD | 27.87% |
| 2019 Q1 | -3.51 Million USD | -9.28% |
| 2018 Q2 | -5.71 Million USD | 24.53% |
| 2018 Q1 | -7.57 Million USD | 47.0% |
| 2018 Q3 | -4.88 Million USD | 14.63% |
| 2018 FY | - USD | 41.81% |
| 2018 Q4 | -3.21 Million USD | 34.18% |
| 2017 Q3 | -694 Thousand USD | 91.91% |
| 2017 Q1 | -13.18 Million USD | 26.31% |
| 2017 Q4 | -14.29 Million USD | -1959.22% |
| 2017 FY | - USD | 27.25% |
| 2017 Q2 | -8.57 Million USD | 34.95% |
| 2016 Q4 | -17.88 Million USD | -83.14% |
| 2016 Q1 | -10.04 Million USD | 12.3% |
| 2016 Q2 | -12.8 Million USD | -27.45% |
| 2016 Q3 | -9.76 Million USD | 23.71% |
| 2016 FY | - USD | -36.15% |
| 2015 Q3 | -15.77 Million USD | -170.79% |
| 2015 Q2 | -5.82 Million USD | -43.91% |
| 2015 Q1 | -4.04 Million USD | 47.54% |
| 2015 FY | - USD | -75.01% |
| 2015 Q4 | -11.45 Million USD | 27.37% |
| 2014 Q2 | -4.74 Million USD | -23.62% |
| 2014 Q1 | -3.83 Million USD | 11.0% |
| 2014 Q4 | -7.71 Million USD | -57.27% |
| 2014 FY | - USD | -72.56% |
| 2014 Q3 | -4.9 Million USD | -3.44% |
| 2013 FY | - USD | 28.66% |
| 2013 Q3 | -3.34 Million USD | -39.03% |
| 2013 Q4 | -4.31 Million USD | -29.0% |
| 2013 Q1 | -2.23 Million USD | 81.16% |
| 2013 Q2 | -2.4 Million USD | -7.76% |
| 2012 Q3 | -1.83 Million USD | -7.19% |
| 2012 Q4 | -11.83 Million USD | -545.26% |
| 2012 FY | - USD | -328.84% |
| 2012 Q2 | -1.71 Million USD | 6.96% |
| 2012 Q1 | -1.83 Million USD | 27.89% |
| 2011 Q1 | -583.02 Thousand USD | 8.56% |
| 2011 Q2 | -134.66 Thousand USD | 76.9% |
| 2011 Q3 | -746.93 Thousand USD | -454.64% |
| 2011 Q4 | -2.55 Million USD | -241.45% |
| 2011 FY | - USD | -227.8% |
| 2010 Q1 | -1 Million USD | -1.63% |
| 2010 FY | - USD | 62.39% |
| 2010 Q2 | 1.05 Million USD | 204.28% |
| 2010 Q4 | -637.62 Thousand USD | 0.82% |
| 2010 Q3 | -642.92 Thousand USD | -161.1% |
| 2009 Q3 | -541.96 Thousand USD | 31.04% |
| 2009 FY | - USD | 52.9% |
| 2009 Q2 | -785.89 Thousand USD | 18.85% |
| 2009 Q1 | -968.46 Thousand USD | -19.84% |
| 2009 Q4 | -992.79 Thousand USD | -83.19% |
| 2008 FY | - USD | 30.43% |
| 2008 Q2 | -1.69 Million USD | 43.83% |
| 2008 Q4 | -808.15 Thousand USD | 41.49% |
| 2008 Q3 | -1.38 Million USD | 18.72% |
| 2008 Q1 | -3.02 Million USD | 3.2% |
| 2007 Q3 | -2.1 Million USD | -16.97% |
| 2007 Q1 | -2.91 Million USD | 28.8% |
| 2007 Q2 | -1.79 Million USD | 38.23% |
| 2007 FY | - USD | -144.71% |
| 2007 Q4 | -3.12 Million USD | -48.58% |
| 2006 Q1 | -515.53 Thousand USD | 0.0% |
| 2006 Q2 | -4363.00 USD | 99.15% |
| 2006 Q3 | 5242.00 USD | 220.15% |
| 2006 FY | - USD | -217.43% |
| 2006 Q4 | -4.08 Million USD | -78103.28% |
| 2005 FY | - USD | 0.0% |
| 2003 Q1 | -574.08 Thousand USD | 28.99% |
| 2002 Q3 | -1.13 Million USD | 62.72% |
| 2002 FY | - USD | 17.04% |
| 2002 Q1 | -3.09 Million USD | -3.92% |
| 2002 Q2 | -3.05 Million USD | 1.22% |
| 2002 Q4 | -808.45 Thousand USD | 29.01% |
| 2001 Q3 | -2.79 Million USD | -18.5% |
| 2001 Q2 | -2.36 Million USD | -45.42% |
| 2001 Q1 | -10.74 Million USD | 14.92% |
| 2001 FY | - USD | -52.05% |
| 2001 Q4 | -2.97 Million USD | -6.38% |
| 2000 Q1 | -1.5 Million USD | -10.9% |
| 2000 Q4 | -1.78 Million USD | -30.0% |
| 2000 Q3 | -1.46 Million USD | 4.37% |
| 2000 Q2 | -1.53 Million USD | -1.87% |
| 2000 FY | - USD | -166.74% |
| 1999 Q2 | -1.33 Million USD | -18.18% |
| 1999 FY | - USD | 18.69% |
| 1999 Q1 | -1.17 Million USD | 0.0% |
| 1999 Q4 | -1.35 Million USD | 2.96% |
| 1999 Q3 | -1.4 Million USD | -7.69% |
| 1998 Q3 | -1.1 Million USD | -103.39% |
| 1998 Q4 | -1.1 Million USD | -175.0% |
| 1998 FY | - USD | 183.51% |
| 1998 Q2 | -700 Thousand USD | 661.9% |
| 1998 Q1 | -2.1 Million USD | -31.25% |
| 1997 Q4 | -1.6 Million USD | 11.11% |
| 1997 Q2 | -3.3 Million USD | -26.92% |
| 1997 Q1 | -2.6 Million USD | -13.04% |
| 1997 FY | - USD | -31.08% |
| 1997 Q3 | -1.8 Million USD | 45.45% |
| 1996 Q1 | -1.6 Million USD | 15.79% |
| 1996 Q2 | -1.6 Million USD | 0.0% |
| 1996 Q4 | -2.3 Million USD | -43.75% |
| 1996 Q3 | -1.6 Million USD | 0.0% |
| 1996 FY | - USD | -1.37% |
| 1995 Q4 | -1.9 Million USD | 5.0% |
| 1995 Q1 | 100 Thousand USD | 101.56% |
| 1995 FY | - USD | -14.06% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q3 | -2 Million USD | -2100.0% |
| 1994 Q2 | 100 Thousand USD | 133.33% |
| 1994 Q1 | -300 Thousand USD | 75.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | - USD | -82.86% |
| 1994 Q4 | -6.4 Million USD | -6500.0% |
| 1993 Q3 | -1.4 Million USD | -250.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q1 | -300 Thousand USD | 0.0% |
| 1993 Q4 | -1.2 Million USD | 14.29% |
| 1993 Q2 | -400 Thousand USD | -33.33% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ADC Therapeutics SA | -146.76 Million USD | 86.472% |
| Alto Neuroscience, Inc. | -34.56 Million USD | 42.555% |
| Annovis Bio, Inc. | -45.03 Million USD | 55.914% |
| Biohaven Pharmaceutical Holding Company Ltd. | -429.13 Million USD | 95.374% |
| Ginkgo Bioworks Holdings, Inc. | -821.29 Million USD | 97.583% |
| Nuvation Bio Inc. | -99.6 Million USD | 80.066% |
| Nuvation Bio Inc. | -99.6 Million USD | 80.066% |
| Arcus Biosciences, Inc. | -283 Million USD | 92.984% |
| Zymeworks Inc. | -129.95 Million USD | 84.723% |